Semaglutide is a medication used for weight management and type 2 diabetes. You may know it by the brand names Ozempic, Wegovy, or Rybelsus.
🍋 The Lemon take
Semaglutide is getting a lot of attention because it can make weight loss and blood sugar control feel more achievable for people who've struggled despite real effort. It can be a powerful tool, but it also comes with real trade-offs, side effects, and limits - it's not a magic solution and it does not replace healthy habits.
What it does
Semaglutide works by acting similarly to a natural hormone (GLP-1) that helps your body:
- Release insulin when your blood sugar is high
- Reduce hunger and cravings
- Slow down how fast your stomach empties
- Lower blood sugar levels
- Support steady weight loss
It's long-acting, so most versions are taken once a week.
Who it's for
- People with type 2 diabetes needing better glucose control
- People with overweight or obesity needing long-term weight management
It is not for type 1 diabetes.
Who should not take it
Avoid semaglutide if you have:
- Personal or family history of certain thyroid cancers (MEN2, medullary thyroid cancer)
- Severe stomach problems like gastroparesis
- A history of pancreatitis
- Pregnancy or breastfeeding
- Type 1 diabetes
Always talk to a clinician first, especially if you have other medical conditions or are taking other medications.
What the research shows
Semaglutide is one of the most studied medications in its class.
Weight loss
In major clinical trial (STEP-1) with randomized, double-blind, placebo-controlled trial with 1,961 individuals, the following results were obtained:
- People lost an average of ~15% of their body weight
- Compared to only ~2% on placebo
Diabetes
In major clinical study (SUSTAIN-6) with 3,297 patients with type 2 diabetes:
Semaglutide lowered major cardiovascular events (cardiovascular death, nonfatal heart attack, or nonfatal stroke) from 8.9% to 6.6% over ~2 years: about 26% lower relative risk.
Other medications in the same family
- Liraglutide (Saxenda, Victoza)
- Dulaglutide (Trulicity)
- Exenatide (Byetta)
- Tirzepatide (Mounjaro, Zepbound) – works on two hormones (GLP-1 + GIP)
Controversies
As GLP-1 medications like semaglutide have been increasingly used off-label for weight loss, demand has surged and that's contributed to supply shortages that can make it harder for people with diabetes to access the drug. And while GLP-1 agonists have been shown to stimulate thyroid C-cell (parafollicular) tumors in rodents, it's not clear how much that finding applies to humans because human thyroid C cells appear to express very few GLP-1 receptors.
References
- Step-1: Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity". The New England Journal of Medicine. 2021. 384(11):989-1002.
- Sustain-6: Marso SP, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes". The New England Journal of Medicine. 2016. 375(18):1834-1844.